PRINCETON, NJ, September 19, 2025 /24-7PressRelease/ -- Oswald F. Bentinck has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Marked by leadership roles across multiple continents and organizations, Mr. Bentinck has built a prominent career spanning 25 years in the pharmaceutical and biotechnology industries. As vice president and global head of value and access at Rocket Pharmaceuticals since 2022, he leads cross-functional teams to align internal stakeholders to ensure clinical trials meet United States Food and Drug Administration and healthcare payer requirements ensuring positive outcomes for patients, payers and healthcare providers.

Mr. Bentinck's responsibilities also include producing evidence to support potential new therapies, educating external stakeholders on the benefits of one-time treatments compared to ongoing costs and navigating healthcare system barriers and pricing rules. By coordinating with payers and treatment centers to ensure patient logistics and support, he and his team ensure that hospitals are educated on proper billing practices for reimbursement. Influenced by a family legacy rooted in civil service and diplomacy, he values constructive influence over adversarial approaches — an ethos reflected throughout all of his endeavors.

Prior to joining Rocket Pharmaceuticals, Mr. Bentinck served as vice president and head of market access at Novartis Gene Therapies from 2020 to 2022. During this period, he played a pivotal role in the launch of Zolgensma, a groundbreaking gene therapy recognized as a blockbuster treatment that generated over $1 billion in annual sales. His efforts were pivotal in securing reimbursement for this innovative therapy in more than 20 countries across Europe and the Middle East. Recognizing the urgency of treating infants affected by neurodegenerative diseases, he initiated the Day One Access program, which enabled patients to receive treatment even before formal approval for pricing and reimbursement was established.

From 2018 to 2020, Mr. Bentinck held the position of vice president, head of market access at AveXis Inc., where he continued to advance market access strategies for gene therapies across Europe, the Middle East and Africa (EMEA). Before that, he was the senior director of value, access and policy across EMEA and Canada at Alexion Pharmaceuticals Inc., where he led the market access team and access initiatives for rare disease therapies.

Over the course of six and a half years at Shire, Mr. Bentinck served as the senior director of global value strategy for rare gastrointestinal diseases from 2016 to 2017, director of global value strategy for angioedema and early commercial development from 2014 to 2016 and held a global marketing role from 2011 to 2014. In each of these capacities, he developed marketing and access strategies for rare disease products, led global and regional market access efforts across the US, Europe, Asia-Pacific, Australia and New Zealand and contributed to early commercial development initiatives.

Mr. Bentinck's earlier experience includes serving on the European brand team in marketing at Pfizer Pharmaceuticals from 2009 to 2011 after working with the Latin America area commercial team in a similar role from 2008 to 2009. Starting his tenure there as part of the regional European marketing team, he led various marketing initiatives for CNS therapies.

Hailing from an equally robust and well-traveled academic background, Mr. Bentinck earned a Master of Laws in tax law from the University of Amsterdam and a Master of Science in health economics policy and management from the London School of Economics and Political Science. His academic achievements have provided him with a strong foundation in both legal frameworks and health finances — skills that have proven invaluable throughout his career as he navigates complex regulatory environments and develops strategies that bridge scientific innovation with real-world patient access.

Along with his education, Mr. Bentinck attributes much of his success to his diverse experiences living around the world — including time spent in the United States during his childhood while his father worked at the United Nations and later at the Dutch embassy in Washington, D.C. He also attended boarding school in England and resided in Europe, Australia and Latin America before returning to the United States. Such cultured experiences have shaped his worldview as a global citizen, fostering an appreciation for different perspectives and priorities.

In his personal life, Mr. Bentinck is a devoted family man with two children — a son who is 15 years old and a daughter who is 12 — both honor students at the Hun School of Princeton. His wife is completing a teaching degree in the Netherlands with plans to work as an elementary school teacher in Princeton upon her graduation. Outside of work, he enjoys going on skiing and hiking trips, playing golf, reading and driving his children to their athletic events.

Looking to the future, Mr. Bentinck aspires to impact the United States cell and gene therapy field by contributing toward improvements in health care access — an area he identifies as critical within the system. Whether it be through future government service or alternative avenues, he hopes that his continued dedication can help drive meaningful change toward broader access to medicine. His journey reflects his commitment not only to advancing innovative therapies but also to ensuring that patients worldwide benefit equitably from medical breakthroughs — a testament to his professional expertise and personal values shaped by a lifetime of global experience.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #